VYGR

Voyager Therapeutics Stock Analysis

AI Rating

Low
  • Quality4/10
  • Growth↓ 2/10
  • Value↓ 0/10
Voyager Therapeutics sales and earnings growth
VYGR Growth
Fair
  • Revenue Y/Y↓ -49.53%
  • EPS Y/Y↓ -80.53%
  • FCF Y/Y↓ -617.24%
Voyager Therapeutics gross and profit margin trends
VYGR Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -296.50%
  • ROIC 5Y↓ 101.16%
Voyager Therapeutics net debt vs free cash flow
VYGR Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Voyager Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗